We hypothesize that the upregulation of the TGFβ signaling pathway might be implicated in the lower proliferation rate of dasatinib-resistant pre-BCR+/E2A-PBX1+ ALL cells, retaining its growth-inhibitory function. Here, PBX1 is linked to acute lymphoblastic leukemia.